secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2026-10-21T13:19:51+00:00
Accession:  0001104659-26-117587
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Abbott to spin off $8.5B Nutrition business via tax-free distribution by end of 2027
--------------------------------------------------------------------------------

- Nutrition spin-off will hold Similac, PediaSure, Pedialyte, Glucerna and Ensure, with ~$8.5B annual sales, ~16,000 employees and 14 manufacturing sites.
- Remaining Abbott will have ~$42B in sales and ~106,000 employees, focused on medical devices, biowearables, diagnostics and established medicines.
- Separation structured as a tax-free distribution to Abbott shareholders; combined Abbott and Nutrition dividends expected to equal Abbott's current payout.
- Daniel Salvadori, EVP and group president of Established Pharmaceuticals and Nutritional Products, will become CEO of the new Nutrition company.
- Abbott reaffirmed 2026 guidance and said 2027 guidance, due in January, is unaffected; one-time transaction charges to be quantified later.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000110465926117587/0001104659-26-117587-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000110465926117587/tm2627971d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-117587

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer